Synribo (Omacetaxine )     CML   Chronic Myeloid Leukemia

Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activity in cells harboring the T315I mutation

SITES

SYNRIBO by Monthly Prescribing Reference

ARTICLES

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
February 2013, American Journal of Hematology

Omacetaxine for Chronic or Accelerated Phase CML Patients with Resistance/Intolerance to Tyrosine Kinase Inhibitors
January 15, 2013, The ASCO Post

FDA Approves Omacetaxine (Synribo) for CML
October 26, 2012, Cancer Network

FDA approves Synribo for chronic myelogenous leukemia
October 26, 2012, FDA

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation
August 15, 2012, PubLMed

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
August 15, 2012, Journal Blood

OMACETAXINE MEPESUCCINATE shows activity in CML patients who have become resistant to or intolerant of prior tyrosine kinase inhibitors (TKIs) (1,2,3)
June 1, 2012, PR Newswire

Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors
June 2012, Nature (Leukemia)

Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 35INS
May 6, 2010, Journal Blood

CML Treatment: Old Drug, New Name – Dr. Cortes           VIDEO
December 12, 2009, ElsGlobalMedicalNews

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML
March 26, 2009, Phys Org